Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Creo Medical ( (GB:CREO) ) has provided an announcement.
Creo Medical has reported accelerating U.S. clinical adoption of its MicroBlate Fine precision microwave ablation platform, which has now been used in more than 50 clinical cases worldwide. The system is being evaluated in an international investigator-led study targeting pancreatic and liver lesions, led by Banner Health in the U.S., with the first patient treated in March 2026.
In a key milestone, MicroBlate Fine enabled the first endoscopic ultrasound-guided microwave ablation of a pancreatic lesion in the U.S., demonstrating its use in complex anatomy. Early uptake at leading U.S. interventional endoscopy centers is expected to support broader market acceptance, drive recurring per-procedure revenues and increase utilisation of Creo’s wider advanced energy ecosystem.
Management said growing site adoption through 2026 should underpin near-term revenue and longer-term penetration in advanced therapeutic endoscopy. Clinicians highlighted that EUS-guided microwave ablation can expand interventional EUS capabilities and broaden treatment options, with early cases reportedly returning very sick patients to routine follow-up with no evidence of disease at first review.
Spark’s Take on CREO Stock
According to Spark, TipRanks’ AI Analyst, CREO is a Neutral.
The score is held back primarily by poor financial performance (sharp revenue decline, large losses, and continued cash burn). Technicals are a partial offset with strong trend and positive MACD, but very overbought RSI increases near-term risk. Valuation impact is neutral since P/E and dividend yield were not provided.
To see Spark’s full report on CREO stock, click here.
More about Creo Medical
Creo Medical Group is a U.K.-listed medical device company focused on minimally invasive electrosurgical technologies for therapeutic endoscopy. Its core CROMA platform, powered by Kamaptive adaptive energy technology, delivers bipolar radiofrequency and high-frequency microwave energy to support cutting, coagulation and ablation, aiming to make endoscopic procedures safer, less invasive and more cost-efficient.
Average Trading Volume: 634,788
Technical Sentiment Signal: Sell
Current Market Cap: £52.07M
Learn more about CREO stock on TipRanks’ Stock Analysis page.